Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 5/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | GAK | O14976 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5128177 | 0.91 | TRPV1 (0.42) | CDK1TRPV1KDRALKRIPK2 | |
| SCHEMBL5128138 | 0.87 | CDK1 (0.43) | CDK1TRPV1KDRALKPOLB | |
| SCHEMBL5122104 | 0.87 | TRPV1 (0.46) | CDK1TRPV1KDRALKRIPK2 | |
| SCHEMBL14209972 | 0.85 | TRPV1 (0.41) | TRPV1KDRALKRIPK2EGFR | |
| SCHEMBL5118647 | 0.82 | TRPV1 (0.42) | TRPV1KDRALKRIPK2EGFR | |
| SCHEMBL5128632 | 0.80 | TRPV1 (0.51) | TRPV1KDRALKRIPK2EGFR | |
| SCHEMBL5121208 | 0.78 | TRPV1 (0.42) | CDK1TRPV1KDRGAKAURKA | |
| SCHEMBL5128092 | 0.78 | TRPV1 (0.47) | CDK1TRPV1KDRALKRIPK2 | |
| SCHEMBL14209971 | 0.76 | TRPV1 (0.45) | TRPV1KDRALKRIPK2EGFR | |
| SCHEMBL5117199 | 0.75 | TRPV1 (0.42) | CDK1TRPV1KDRGAKAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954133-A2 | PYRROLIDINEANILINES | SMITHKLINE BEECHAM CORPORATION (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20080085901-A1 | Heteroaryl Substituted Quinolin-4-Ylamine Analogues | NEUROGEN CORPORATION (US) | 2008-04-10 | — | — | US | disclosed |
| US-20080085901-A1 | Heteroaryl Substituted Quinolin-4-Ylamine Analogues | NEUROGEN CORPORATION (US) | 2008-04-10 | — | — | US | disclosed |
| US-20080085901-A1 | Heteroaryl Substituted Quinolin-4-Ylamine Analogues | NEUROGEN CORPORATION (US) | 2008-04-10 | — | — | US | disclosed |
| EP-1836203-A2 | HETEROARYL SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2007065093-A2 | PYRROLIDINEANILINES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2006076646-A2 | HETEROARYL SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085901-A1 | Heteroaryl Substituted Quinolin-4-Ylamine Analogues | PIGS, GPR52, GPR174 | CDK1 4019/4885TRPV1 477/4885KDR 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.